---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-037174"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:18:58.630564+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Avalo shareholders approve equity plan increase to 3.55M shares, ESPP, and elect directors

## Summary
- Stockholders approved Fourth Amended and Restated 2016 Equity Incentive Plan, increasing share reserve to 3,548,882 shares with automatic annual increases through 2034.
- Stockholders also approved Amended and Restated Employee Stock Purchase Plan, reserving 234,878 shares with automatic annual increases through 2034.
- All seven director nominees were elected: June Almenoff, Mitchell Chan, Jonathan Goldman, Aaron Kantoff, Gilla Kaplan, Garry Neil, Samantha Truex.
- Stockholders ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2024.
- Proposal to approve issuance of shares for Series C Preferred conversion, warrant exercise, and AlmataBio milestone obligations was approved.

## SEC filing metadata
- accession: 0001628280-24-037174
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024037174/0001628280-24-037174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024037174/avtx-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-037174
- JSON: https://secwatch.observer/filing/0001628280-24-037174.json
- Plain text: https://secwatch.observer/filing/0001628280-24-037174.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.